# ZTS — Zoetis · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ZTS  
**Sources:** 30  
**Published:** 2026-08-05  
**Canonical:** https://app.k3vl4r.com/research/deep-research-zts-zoetis-catalysts-narrative-risks-989

---

# Zoetis (ZTS) Research Summary — As of August 16, 2026

## Recent Key Catalysts (Last ~1–3 Months)

### Q2 2026 Earnings (August 6, 2026)
Zoetis reported Q2 2026 earnings on August 6, 2026, posting EPS of $1.87, which narrowly beat the consensus estimate of $1.86 by approximately 0.54% [[12]](https://public.com/stocks/zts/earnings). However, revenue came in at $2.468 billion, missing estimates by roughly 0.95% [[9]](https://www.quiverquant.com/news/ZOETIS+($ZTS)+Releases+Q2+2026+Earnings)[[10]](https://www.zacks.com/stock/news/2969597/zoetis-zts-surpasses-q2-earnings-estimates). Year-over-year, EPS grew from $1.76 in Q2 2025 [[12]](https://public.com/stocks/zts/earnings), though the overall tone was mixed. Management revised full-year guidance downward, reflecting a challenging U.S. companion animal market and increased competition [[1]](https://finance.yahoo.com/healthcare/articles/zoetis-inc-zts-q2-2026-231635664.html).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-zts-zoetis-catalysts-narrative-risks-989 (free to sign up)._